These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 10037394)

  • 41. Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction.
    Gao CL; Dean RC; Pinto A; Mooneyhan R; Connelly RR; McLeod DG; Srivastava S; Moul JW
    J Urol; 1999 Apr; 161(4):1070-6. PubMed ID: 10081840
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.
    Lau WK; Bergstralh EJ; Blute ML; Slezak JM; Zincke H
    J Urol; 2002 Jan; 167(1):117-22. PubMed ID: 11743287
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
    Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
    J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Changes in circulating immunosuppressive cytokine levels of cancer patients after high intensity focused ultrasound treatment.
    Zhou Q; Zhu XQ; Zhang J; Xu ZL; Lu P; Wu F
    Ultrasound Med Biol; 2008 Jan; 34(1):81-7. PubMed ID: 17854983
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.
    Small EJ; Reese DM; Um B; Whisenant S; Dixon SC; Figg WD
    Clin Cancer Res; 1999 Jul; 5(7):1738-44. PubMed ID: 10430077
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum keratinocyte growth factor measurement in patients with prostate cancer.
    Mehta PB; Robson CN; Neal DE; Leung HY
    J Urol; 2000 Dec; 164(6):2151-5. PubMed ID: 11061946
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer.
    Rich T; Innominato PF; Boerner J; Mormont MC; Iacobelli S; Baron B; Jasmin C; Lévi F
    Clin Cancer Res; 2005 Mar; 11(5):1757-64. PubMed ID: 15755997
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
    Graefen M; Karakiewicz PI; Cagiannos I; Hammerer PG; Haese A; Palisaar J; Huland E; Scardino PT; Kattan MW; Huland H
    J Urol; 2002 Mar; 167(3):1306-9. PubMed ID: 11832719
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Study of prostate cancer pathologic features in Chinese populations.
    Chuang AY; Chang SJ; Horng CF; Tsou MH
    Urology; 2007 May; 69(5):915-20. PubMed ID: 17482934
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatocyte growth factor and interleukin-6 in combination with prostate volume are possible prostate cancer tumor markers in patients with gray-zone PSA levels.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Namba Y; Kishikawa H; Takahara S; Ichikawa Y
    Prostate Cancer Prostatic Dis; 2008; 11(3):258-63. PubMed ID: 17876341
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy.
    Shariat SF; Shalev M; Menesses-Diaz A; Kim IY; Kattan MW; Wheeler TM; Slawin KM
    J Clin Oncol; 2001 Jun; 19(11):2856-64. PubMed ID: 11387358
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
    Tarle M
    Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer.
    Nakashima J; Sumitomo M; Miyajima A; Jitsukawa S; Saito S; Tachibana M; Murai M
    J Urol; 1997 May; 157(5):1736-9. PubMed ID: 9112516
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transforming growth factors-beta 1 and beta 2 in serum and urine from patients with bladder carcinoma.
    Eder IE; Stenzl A; Hobisch A; Cronauer MV; Bartsch G; Klocker H
    J Urol; 1996 Sep; 156(3):953-7. PubMed ID: 8709371
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression.
    Shariat SF; Kattan MW; Traxel E; Andrews B; Zhu K; Wheeler TM; Slawin KM
    Clin Cancer Res; 2004 Mar; 10(6):1992-9. PubMed ID: 15041717
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epidermal growth factor (EGF) promotes chemomigration of a human prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone.
    Rajan R; Vanderslice R; Kapur S; Lynch J; Thompson R; Djakiew D
    Prostate; 1996 Jan; 28(1):1-9. PubMed ID: 8545275
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum transforming growth factor-beta1 in patients with renal cell carcinoma.
    Wunderlich H; Steiner T; Junker U; Knöfel B; Schlichter A; Schubert J
    J Urol; 1997 May; 157(5):1602-3. PubMed ID: 9112485
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TGF-beta1 and TNF-alpha after red blood cell transfusion in colorectal cancer patients.
    Milasiene V; Stratilatovas E; Characiejus D; Kazbariene B; Norkiene V
    Exp Oncol; 2007 Mar; 29(1):67-70. PubMed ID: 17431392
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer.
    Wakefield LM; Letterio JJ; Chen T; Danielpour D; Allison RS; Pai LH; Denicoff AM; Noone MH; Cowan KH; O'Shaughnessy JA
    Clin Cancer Res; 1995 Jan; 1(1):129-36. PubMed ID: 9815895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.